Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: treatment

  • Zilucoplan Injection (Zilbrysq)

    The U.S. Food and Drug Administration has approved a once-daily subcutaneously administered drug for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive. Zilucoplan is macrocyclic peptide that inhibits the cleavage of complement 5 (C5) to C5a and C5b.

  • Brain Atrophy and Type 1 Diabetes

    In a long-term longitudinal study of people with type 1 diabetes, excessive brain atrophy and cognitive dysfunction were noted compared to healthy controls. The investigators calculated that type 1 diabetes resulted in six years of accelerated brain aging and brain atrophy that was separate and distinct from Alzheimer’s disease.

  • Multicomponent Intervention for Early Detection and Treatment of Postpartum Hemorrhage: E-MOTIVE

    This international, parallel, cluster-randomized trial assigned 80 secondary-level hospitals in four African countries to evaluate a multicomponent intervention for early detection and treatment of postpartum hemorrhage (PPH) vs. usual care following a vaginal birth. The intervention group had 60% less severe PPH cases (> 1 L blood loss) than the usual care cohort.

  • Comparison of the Efficacy of Rituximab vs. Ocrelizumab in the Treatment of Relapsing Multiple Sclerosis

    Rituximab is an anti-CD20 chimeric monoclonal antibody used off-label to treat multiple sclerosis (MS). Ocrelizumab is a humanized monoclonal anti-CD20 monoclonal antibody that is Food and Drug Administration-approved for the treatment of MS. In this observational cohort study, the authors were not able to demonstrate noninferiority of rituximab compared to ocrelizumab because of a significantly lower relapse rate in the ocrelizumab-treated group.

  • Treatment of Preclinical Alzheimer’s Disease

    After a four-year, complex clinical trial of an anti-amyloid antibody, solanezumab, there was no benefit in reducing the likelihood of progression of cognitive impairment in patients with positive amyloid positron emission tomography scans who started the trial cognitively unimpaired vs. placebo.

  • Super-Refractory Status Epilepticus: Clinical Characteristics, Treatment, and Outcome

    Patients with super-refractory status epilepticus (SRSE) differed from patients with first-time status epilepticus in clinical presentations and the treatment course. Although seizure control was achieved in most SRSE patients, the in-hospital mortality and the chance of severe disability at discharge were high.

  • Endometriosis and the Gut Microbiome: Nutritional Prospects in the Treatment of a Chronic Disease

    Endometriosis is characterized by the presence of endometrial glands and stroma in any extrauterine site, such as the ovary, fallopian tubes, pelvic peritoneum, rectovaginal space, bowel, and, rarely, lungs and brain. Standard treatment of endometriosis may involve the use of pain relievers such as nonsteroidal anti-inflammatory drugs, hormonal therapy and modulators, and/or surgical removal of endometriotic tissue. On average, women seek consultation from three different healthcare providers over several years to receive a diagnosis of endometriosis. The delay in care results in significant long-term morbidity.

  • Emerging Treatment for Refractory Vasodilatory Shock

    Shock is a common cause for intensive care unit admission, necessitating rapid treatment of the underlying cause while supporting patients with fluids and vasopressor agents. Typical vasopressor agents include adrenergic agonists and vasopressin. When shock persists despite these interventions, this is labeled refractory shock.

  • Does Treatment of Gestational Diabetes Before 20 Weeks of Gestation Improve Pregnancy Outcomes?

    Therapy for gestational diabetes diagnosed before 20 weeks of pregnancy was associated with a slightly decreased frequency of a composite of unfavorable neonatal outcomes compared to deferred treatment or no therapy. No significant changes were demonstrated for pregnancy-related hypertension or neonatal lean body mass between the two groups.

  • Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant

    In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.